Repare Therapeutics (NASDAQ:RPTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Repare Therapeutics (NASDAQ:RPTX) to a hold rating in a report published on Saturday morning.

Several other brokerages have also weighed in on RPTX. HC Wainwright decreased their target price on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Repare Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.50.

Repare Therapeutics Trading Up 32.1%

Shares of NASDAQ:RPTX opened at $2.18 on Friday. The firm has a market capitalization of $93.65 million, a PE ratio of -1.29 and a beta of 1.06. Repare Therapeutics has a 1-year low of $0.89 and a 1-year high of $4.07. The business’s 50 day moving average is $1.79 and its 200-day moving average is $1.59.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Friday, November 14th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.43. The firm had revenue of $11.62 million during the quarter, compared to the consensus estimate of $7.50 million. On average, sell-side analysts predict that Repare Therapeutics will post -2.04 EPS for the current year.

Hedge Funds Weigh In On Repare Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC increased its holdings in shares of Repare Therapeutics by 35.6% during the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after buying an additional 168,230 shares in the last quarter. Rangeley Capital LLC acquired a new position in shares of Repare Therapeutics in the 2nd quarter worth approximately $494,000. Affinity Asset Advisors LLC grew its position in Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after acquiring an additional 100,000 shares during the last quarter. Militia Capital Partners LP acquired a new stake in Repare Therapeutics during the 2nd quarter valued at $166,000. Finally, Squarepoint Ops LLC bought a new position in Repare Therapeutics in the 3rd quarter valued at $115,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.